Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: we’re seeing selective evidence of a rebound

September 12, 2018 8:35pm

The sector rose for the second session as NASDAQ got whipped

We'll need to see some further follow-through to take risk out of the upside support

Pre-open indications: 4 HIT and 1 MISS

We crave explanations because they give us an illusion of control. Who is feeding your portfolio - profit from RMi’s analysis!

Henry’omics:

After waffling between positive and negative territory throughout the day, sector equities managed to extend its gains on Wednesday following second up session.

There is caution and woory in the wind - I'm NOT depending on sustainability!

From the pre-open newsletter: “fasten your seatbelts, it’s sessions of starts and stops. Alternating volatility with low volume has left many equities collaterally damaged; thus any rebound is a catch-up in a battle for pricing sustainability.”

I also stated, “As far as “our” universe, we are left at the mercy of the NADAQ – I’d been hoping to be the safe haven for the volatile sector but, low volume and no news have left us with decreased momentum!”

I also wrote last week (9/6), “Humpty-Dumpty (the sector) had a great fall and all the trading horses and all the retail and institutional men won’t put Humpty totally together again – for a while.”

The spits and spurts:

AGTC flipped positive (+$0.03) after getting nailed post Q4 and FY18 reporting (-$0.375);

BLFS declined another -$0.50 after Tuesday’s -$0.44, as I had stated - another Icarus flight pattern;

VSTM dropped -$0.31 after Tuesday appreciation of +$0.12 with increasing volume – October is getting closer, are investor feeling negative (?) or just profiting;

BSTG closed down -$0.30 after being flat at $3.40 in a holding cell (my OPINION, the reverse split criminals will reputationally pay the price;

HSGX was down -$0.0167 after being up, the shell and cash is worth more than +$0.64;

BLUE (-$5.45) after yesterday’s -$5.00 is still “fast and furious” today to the downside;

RGNX slip -$1.55 after yesterday’s gain of +$1.90, so much for regaining altitude

The CRISPR trio CRSP closed up +$1.93 after yesterday’s +$2.11, EDIT closed up +$0.25 after yesterday’s +$1.17 and NTLA closed up +$1.14 after Tuesday’s +$2.015 - still retracing lost value until the next decline (I wouldn’t hold my breath) – trading vehicles;

Caladrius Bioscience (CLBS) closed down -$0.09 on yet another session with small volume (24.56 K shares traded) after Tuesday’s +$0.14 on small volume (17.25 K shares traded – 3 month average = 329.2 K) – if you had read last night’s review – CLBS is an “egg salad sandwich” which has been on the shelf too long, it could be called a portfolio “ptomaine” in time;

Of the 45 companies covered on Wednesday; 20 downside equities finished in a range of -0.97% (GBT) to -11.08% (AXGN) while 25 upside equity oscillated from +0.07% (ONCE) to +16.65% (SLDB) with 0 flat closes.

Daily analytics and metrics:

The Dow closed up +27.86 points or +0.11% to 25,998.92
The S&P closed up +1.03 points and +0.04% to 2,888.92
The NASDAQ closed down -18.25 points or -0.23% to 7,954.23

The advance/decline line scenario of 45 covered companies:

The open was negative with an A/DL of 16/25 and 3 flats;
The mid-day flipped positive with an A/DL of 27/16 and 2 flats;
1:30 p.m. was negative with an A/DL of 20/24 and 1 flat;
The close flipped positive with an A/DL of 25/20 and 0 flats;

Pre-open indications: 4 HIT and 1 Miss

Asterias Biosciences (NYSEMKT: AST) closed up +$0.05 – hit;
bluebird bio (BLUE) closed down -$5.45 – hit;
CRISPR Therapeutics (CRSP) closed up +$1.93 – miss;
Editas Medicine (EDIT) closed up +$0.25 – hit;
Intellia Therapeutics (NTLA) closed up +$1.14 – hit;

Four (4) key metrics:

… The greatest volume to the downside: ALNY, VSTM, MDXG, SGMO and HSGX

… Upside volume was weighted to: BMRN, IONS, SLDB, ATHX and XON

… Leadership ($) to the downside: (ALNY (-$5.600, BLUE (-$5.45), AXGN (-$4.500, SAGE (-$4.18) and RGNX (-$1.55)

… Best moves ($) to the upside: SLDB (+$7.23), RENE.L (+$2.00), CRSP (+$1.93), BMRN (+$1.87) and FIXX (+$1.15)

The iShares NASDAQ Biotechnology (IBB) closed:

Wednesday was up +0.05%
Tuesday was down -0.42%
Monday was up +0.17%
Friday was down -0.57%
Thursday was down -1.78%
Last Wednesday was down -0.30%

September sessions:

Wednesday’s closed POSITIVE with 20 decliners, 25 advancer and 0 flats

Tuesday’s closed POSITIVE with 20 decliners, 23 advancer and 2 flats

Monday’s closed NEGATIVE with 28 decliners, 17 advancer and 2 flats

Friday’s closed POSITIVE with 15 decliners, 23 advancer and 7 flats

Thursday’s closed NEGATIVE with 39 decliners, 1 advancer and 5 flats

Wednesday’s closed NEGATIVE with 30 decliners, 12 advancers and 3 flats

Tuesday’s (9/4) closed NEGATIVE with 22 decliners, 19 advancers and 4 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.